PASG Passage BIO, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1787297 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY26.9%
TTM EPS YoY27.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-212.3%
ROA-69.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets99.8%
Debt / equity0.00x
Current ratio1.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-0.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $23.28M | $40.18M | $61.42M | $86.05M | $117.67M |
| SG&A expense | $19.88M | $24.99M | $41.58M | $49.34M | $60.06M |
| Operating income | -$49.30M | -$70.40M | -$108.39M | -$138.39M | -$185.73M |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$45.52M | -$64.77M | -$102.06M | -$136.12M | -$185.39M |
| EBITDA | -$48.57M | -$67.32M | -$104.67M | -$134.72M | -$184.19M |
| EPS (basic) | -14.35 | -21.04 | -1.86 | -2.50 | -3.48 |
| EPS (diluted) | -14.35 | -21.04 | -1.86 | -2.50 | -3.48 |
| Weighted avg. shares (diluted) | 3.17M | 3.08M | 54.74M | 54.43M | 53.34M |
| Balance sheet | |||||
| Cash & equivalents | $46.30M | $37.57M | $21.71M | $34.60M | $128.97M |
| Short-term investments | $0 | $39.18M | $92.58M | $155.01M | $186.81M |
| Current assets | $47.76M | $78.81M | $117.96M | $197.04M | $325.07M |
| PP&E, net | $4.11M | $9.33M | $15.29M | $22.52M | $23.81M |
| Total assets | $62.28M | $102.41M | $150.54M | $243.55M | $355.08M |
| Current liabilities | $23.08M | $19.36M | $16.34M | $18.35M | $29.50M |
| Total liabilities | $43.53M | $41.15M | $39.26M | $42.18M | $36.42M |
| Shareholders' equity | $18.75M | $61.26M | $111.28M | $201.37M | $318.66M |
| Shares outstanding | 3.18M | 3.16M | 54.94M | 54.61M | 54.24M |
| Cash flow statement | |||||
| Operating cash flow | -$31.51M | -$47.96M | -$78.26M | -$118.21M | -$126.88M |
| Capital expenditure | — | $34,000 | — | — | — |
| Free cash flow | — | -$47.99M | — | — | — |
| Investing cash flow | $40.22M | $54.95M | $65.24M | $25.20M | -$45.81M |
| Financing cash flow | $23,000 | $8.87M | $135,000 | -$1.35M | $166.66M |
| Depreciation & amortization | $728,000 | $3.08M | $3.72M | $3.68M | $1.54M |
| Stock-based compensation | $3.00M | $5.82M | $10.92M | $18.95M | $32.69M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.